Abilify

  • Abilify Side Effects & Symptoms Lawsuit Medical Record Review | Neural IT

Abilify (aripiprazole) is an atypical antipsychotic manufactured by Otsuka Pharmaceutical Co., Ltd marketed jointly with Bristol-Myers Squibb Canada. It was approved by FDA in November 2002 for the treatment of Schizophrenia. In 2007, FDA approved Aripiprazole for treatment of Unipolar depression as an adjunct with an antidepressant medication. The drug works by either increasing or decreasing dopamine or serotonin levels in the brain when there is an imbalance.

A large number of patients treated with Abilify were reported to develop habit of compulsive gambling and got racked up with large amounts of debts. Other pathological behaviors like excessive eating, excessive shopping and Hypersexuality is also noted who started using or increased dosage of Abilify.

Young patients with depression and elderly patients with dementia consuming Abilify are found to be at a high risk of suicidal thoughts or actions. It also increases risk of developing diabetes.

Serious Alleged Injuries may include:

  • Pathological Gambling
  • Binge Eating
  • Hypersexuality
  • Dementia Suicide Risk

FDA Safety Warnings:

  • In 2004, the Food and Drug Administration (FDA) issued a black-box warning on antidepressants indicating that they were associated with an increased risk of suicidal thinking, feeling, and behavior in young people.
  • On April 11, 2005, FDA required another black box warning: Increased Mortality in Patients with Dementia-Related Psychosis. In 2006 the FDA required the companies to add a black box warning to the label, warning that older people who were given the drug for dementia-related psychosis were at greater risk of death.
  • On May 3, 2016, FDA warned that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole.

Lawsuit Allegations:

The Abilify lawsuits claim the manufacturers of the medication failed to warn doctors and patients that the drug could cause compulsive behaviors, such as gambling, shopping, eating, and sex.

Abilify lawsuits were consolidated in October 2016, in MDL No. 2734 (In Re: Abilify Compulsive Behavior Products Liability Litigation) to be presided by Chief Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida. 

Trials to begin the end of 2017.

A parallel state court litigation has been established in New Jersey, where Superior Court Judge James De Luca is presiding over all cases filed in the state, and established a bellwether track where the first trials could begin by the end of 2018.

Evidences:

  • Usage in Pharmacy Records
  • Duration of Usage
  • Indication of usage in Medical Records

Medical Record Review and claim validation of Abilify case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.

Accreditations

HIPAA

Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...

NSIC - CRISIL

NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...

Associations

CAALA

CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...

CAOC

CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...

NYSTLA

NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

‘Rewards & Recognition Program’ Celebrations
‘Rewards & Recognition Program’ Celebrations!
Hurricane Relief Fund
We donated to Hurricane Relief Fund and got a signed ball from Kareem Abdul-Jabbar, the greatest
AAJ Annual Convention 2017
Neural IT sponsored TRT meeting was one of the active participants of AAJ Annual Convention 2017.

Latest Tweets